Clinical Trial: Tirzepatide in Individuals With Alcohol Use Disorder and Metabolic Alcohol-Associated Liver Disease

U.S., July 3 -- ClinicalTrials.gov registry received information related to the study (NCT07046819) titled 'Tirzepatide in Individuals With Alcohol Use Disorder and Metabolic Alcohol-Associated Liver Disease' on July 01.

Brief Summary: Background:

People with alcohol use disorder (AUD) often develop metabolic alcohol-associated liver disease (MetALD). MetALD is a term for the heart, liver, obesity, and other issues that can accompany AUD. MetALD can be fatal. An approved weight management drug (Tirzepatide) may be able to help people with AUD and MetALD control their alcohol intake.

Objective:

To test Tirzepatide in people with AUD and MetALD.

Eligibility:

People aged 21 years and older with AUD and MetALD.

Design:

Participants will...